Članak
jun 10
Nazad

NEDOZVOLJENI SPORAZUMI U VEZI SA FARMACEUTSKIM PRONALASCIMA

Stefan Šokinjov

10.55836/Zbornik_PiP_2301A
SAŽETAK /

Tzv. originerne lekove proizvode one farmaceutske kompanije koje su nosioci patenata na pronalaske u vezi sa aktivnim hemijskim ili biološkim sastojcima. Sve dok traje patentna zaštita originerni lekovi se prodaju po monopolskim cenama. Pošto su patenti vremenski ograničena subjektivna prava, prodaja po ovim cenama traje privremeno. Kako bi produžili period tržišne ekskluzivnosti originernog leka farmaceutske kompanije, između ostalog, plaćaju proizvođačima generičnih lekova za odlaganje ulaska na tržište. Pošto se na taj način narušava cenovna konkurencija učesnici ovih sporazuma, koji se često zaključuju u formi poravnanja, kažnjeni su u administrativnom postupku. Osporeni upravni akti su kasnije potvrđeni od strane Suda pravde Evropske unije u slučaju Lundbeck i Apelacionog tribunala V. Britanije za pravo konkurencije u slučaju Generics (a u kom slučaju je Sud pravde EU rešavao po prethodnom pitanju).

ČLANAK JE RASPOLOŽIV NA /
Ćirilici  
REFERENCE /
  1. Geradin Damien, „When Competition Law Analysis Goes Wrong – The Italian Pfizer/Pharmacia Case“, dostupno na adresi: https://papers. ssrn.com/sol3/papers.cfm?abstract_id=2393383, 12. 12. 2022.
  2. Gratz Linda, „Economic Analysis of Pay-for-Delay Settlements and Their Legal Ruling“, Munich Discussion Paper, Nr. 6/2012.
  3. Ibaňez Colomo Pablo, „The legal status of pay-for-delay agreements in EU competition law: Generics (Paroxetine), dostupno na adresi: https:// papers.ssrn.com/sol3/papers.cfm?abstract_id=3693746, 12. 12. 2022.
  4. Jovanović Slobodanka, „Patents in the Pharmaceutical Industry“, Chemical Industry, Nr. 3/2003.
  5. Laszcyk Anna, „Anticompetitive Patent Settlements – Where Are We Ten Years After the European Commission’s Pharmaceutical Inquary?“, Yearbook of Antitrust and Regulatory Studies, Nr. 21/2022.
  6. Lianos Ioanis, Korah Valentine, Siciliani Paolo, Competition Law: Analysis, Cases and Materials, London 2017.
  7. Oliveira Pais Sofia, „The Lundbeck Case through the Lens of Probabilistic Patents“, The Lundbeck Case and the Concept of Potential Competition (ime urednika nepoznato), Institute of Competition Law, 2017.
  8. Feldman Robin, Misra Prianka, „The Fatal Attraction of Pay-for-Delay“, Chicago-Kent Journal of Intellectual Property, Nr. 1/2019.
  9. Hancher Leigh, Sauter Wolf, „A dose of competition: EU antitrust law in the pharmaceutical sector“, TILEC, Nr. 17/2015.
  10. Hemphil Scott, „Drug Patent Settlements Between Rivals: A Survey“, do- stupno na adresi: https://papers.ssrn.com/sol3/papers.cfm?abstract_ id=969492, 12. 12. 2022.
  11. Hemphill Scott, „Paying for Delay: Pharmaceutical Patent Settlement as a Regulatory Design Problem“, dostupno na adresi: https://papers.ssrn. com/sol3/papers.cfm?abstract_id=925919, 12. 12. 2022.
  12. Hovenkamp Herbert, „Innovation and Competition Policy, Chapter 4(2d): Competition Policy and the Patent System“, dostupno na adresi: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=1938310, 12. 12. 2022.